Financial Performance - The group's revenue for the year ended March 31, 2023, was approximately HKD 227.6 million, an increase of about HKD 48.0 million or 26.7% compared to approximately HKD 179.6 million for the year ended March 31, 2022[10]. - The net profit for the year ended March 31, 2023, was approximately HKD 16.4 million, compared to a net loss of approximately HKD 8.8 million for the previous year[11]. - Other income for the year ended March 31, 2023, was approximately HKD 6.0 million, up from HKD 5.6 million in the previous year, primarily due to increased government subsidies[24]. - Employee costs for the year ended March 31, 2023, were approximately HKD 80.3 million, an increase from HKD 69.3 million in the previous year, attributed to fewer temporary closures of medical beauty centers[25]. - The total equity of the company as of March 31, 2023, was approximately HKD 19.5 million, compared to HKD 3.1 million in the previous year[34]. - The company reported a revenue from its top five customers of less than 1.42% for the year ending March 31, 2023, compared to 2.5% in 2022[83]. - The largest supplier accounted for approximately 13.4% of the total procurement for the year ending March 31, 2023, down from 31.3% in 2022[83]. - Total procurement from the top five suppliers represented about 46.5% of the company's total procurement for the year ending March 31, 2023, compared to 63.1% in 2022[83]. Revenue Growth Factors - The significant revenue increase was attributed to fewer days of mandatory closure for medical beauty centers and improved consumer sentiment due to the containment of COVID-19[15]. - The government’s consumption voucher scheme and the company's ongoing marketing efforts also contributed to the substantial revenue growth[15]. - The company plans to continue expanding its operations by opening new centers to capture growing customer demand[19]. - The company will monitor market conditions closely and develop sustainable strategies to seize opportunities in the current environment[20]. Strategic Plans and Outlook - The company remains optimistic about the industry outlook and plans to continue strategic business expansion and effective marketing activities to achieve sustained growth[15]. - The company will assess development opportunities to strengthen its competitive advantage and consolidate its leading position in the industry[15]. - The company intends to expand the range of services offered by acquiring new treatment equipment and consumables[15]. Shareholder and Governance Matters - The company has no distributable reserves available for shareholders as of March 31, 2023, consistent with the previous year[81]. - The board does not recommend the payment of a final dividend for the year ending March 31, 2023[76]. - The company has a significant shareholder structure, with both Mr. Ye and Ms. Fu holding 514,500,000 shares each, representing 64.31% of the total shares post-offering[92]. - Equal Joy, a major shareholder, is jointly owned by Mr. Ye and Ms. Fu, each holding a 50% stake[93]. - The company aims to attract and retain qualified individuals through its share option plan to enhance contributions to the group's interests[101]. - The board of directors includes Mr. Ye as the chairman and Ms. Fu as the CEO, with independent non-executive directors ensuring governance[91]. - The company has received annual confirmations from independent non-executive directors regarding their independence[92]. - The company has established a stock option plan with a maximum issuance of shares not exceeding 1% of the total issued shares within any 12-month period[104]. Risk Management and Compliance - The company has identified various risks that could adversely affect its financial condition and operational performance, including economic and political instability in Hong Kong[71]. - The company is committed to complying with applicable environmental laws and minimizing negative impacts on the environment[72]. - The company has established risk management procedures and guidelines to identify potential risks affecting business operations[176]. - An independent internal control consultant has been appointed to review the effectiveness of the internal control system annually[177]. - The board believes that the risk management and internal control systems are effective and sufficient as of March 31, 2023[178]. Employee and Operational Matters - As of March 31, 2023, the group had a total of 201 employees, an increase from 159 employees in 2022[36]. - The company made charitable donations of approximately HKD 63,000 for the year, an increase from HKD 19,000 in 2022[85]. - The company has maintained good relationships with employees, customers, and suppliers, with no significant disputes reported for the year ending March 31, 2023[74]. Financial Position and Assets - The debt-to-equity ratio as of March 31, 2023, was 340.37%, a significant decrease from 3,015.17% in 2022, primarily due to an increase in the group's net asset value[39]. - The group had approximately HKD 14.4 million in secured and unsecured bank borrowings as of March 31, 2023, compared to approximately HKD 14.3 million in 2022[45]. - The company purchased property, plant, and equipment amounting to approximately HKD 32.2 million for the year ended March 31, 2023, down from HKD 45.7 million in the previous year[35]. - The group incurred lease property renovation expenses of approximately HKD 1,530,000 as of March 31, 2023, slightly down from HKD 1,548,000 in 2022[42]. - The company announced the sale of its wholly-owned subsidiary, Maosheng Limited, for a consideration of HKD 23,000,000, with a cash payment of HKD 2,000,000 due at signing[47]. Corporate Governance and Board Activities - The audit committee reviewed the audited consolidated financial statements for the year ended March 31, 2023, ensuring compliance with applicable accounting standards and GEM listing rules[132]. - The board of directors consists of five members, including two executive directors and three independent non-executive directors, ensuring compliance with GEM listing rules[141]. - The company has adopted the corporate governance code as per GEM listing rules and has complied with all applicable provisions during the year[137]. - The company’s independent non-executive directors have confirmed their independence in accordance with GEM listing rules[148]. - The company has not entered into any stock-linked agreements during the year[127]. - The board regularly reviews and manages its capital structure to ensure optimal capital structure and shareholder returns, considering various factors including financial performance and capital needs[199].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就 因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 Fameglow Holdings Limited 亮 晴 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8603） 截 至 二 零 二 三 年 三 月 三 十 一 日 止 年 度 之 全 年 業 績 公 告 亮晴控股有限公司（「本公司」）之董事（「董事」）會（「董事會」）欣然公佈本公 司及其附屬公司（統稱「本集團」）截至二零二三年三月三十一日止年度之 全 年 業 績 連 同 比 較 數 字。本 公 告 載 有 本 公 司 二 零 二 二╱二 零 二 三 年 年 度 報 告 全 文，符 合 香 港 聯 合 交 易 所 有 限 公 司GEM證 券 上 市 規 則（「GEM上 市 規 則」）有 關 隨 附 全 年 業 績 初 步 公 告 的 資 料 的 規 定。本 公 司 二 零 二 二╱二 零 二 三 年 年 度 報 告 印 刷 本 將 適 時 寄 發 予 本 公 司 股 東，並 ...

Financial Performance - For the nine months ended December 31, 2022, the group's revenue was approximately HKD 154.0 million, a decrease of 12.2% compared to HKD 175.5 million for the same period in 2021[7]. - The net profit for the nine months ended December 31, 2022, was approximately HKD 2.1 million, down 83.3% from HKD 12.6 million in the same period of 2021[7]. - The group's pre-tax profit was HKD 2.23 million, down 81.7% from HKD 12.22 million in the previous year[9]. - The total comprehensive income for the period was HKD 2.1 million, a significant decrease from HKD 12.57 million in the same period last year[9]. - Basic earnings per share decreased to HKD 0.26 from HKD 1.57, a decline of 83.4%[9]. - Revenue for the nine months ended December 31, 2022, was approximately HKD 154.0 million, a decrease of about HKD 21.5 million or 12.3% compared to HKD 175.5 million in the same period of 2021[33]. - The profit for the nine months ended December 31, 2022, was approximately HKD 2.1 million, down from HKD 12.6 million in the same period of 2021[33]. - Revenue from treatment services was HKD 150.9 million for the nine months ended December 31, 2022, compared to HKD 170.4 million in 2021, reflecting a decline of approximately 11.4%[19]. Costs and Expenses - The group's cost of inventory and consumables was HKD 19.2 million, compared to HKD 29.2 million in the prior year, reflecting a decrease of 34.3%[9]. - Employee costs increased to HKD 62.97 million from HKD 56.83 million, representing an increase of 10.5% year-on-year[9]. - Depreciation of property, plant, and equipment rose to HKD 19.4 million from HKD 13.1 million, an increase of 48.0%[9]. - The company’s marketing and promotion expenses for the nine months ended December 31, 2022, were HKD 14.3 million, down from HKD 20.6 million in 2021[22]. - Total other expenses decreased to approximately HKD 33.1 million for the nine months ended December 31, 2022, from HKD 39.6 million in the same period of 2021, mainly due to reduced promotional activities[45]. - The company’s depreciation expenses for property, plant, and equipment increased to HKD 19.4 million in 2022 from HKD 13.1 million in 2021[22]. - Inventory and consumables cost for the nine months ended December 31, 2022, was approximately HKD 19.2 million, down from HKD 29.2 million in the same period of 2021, reflecting a decrease in revenue[37]. Dividends - The board of directors did not recommend any dividend for the nine months ended December 31, 2022, consistent with the previous year[7]. - The company did not declare any dividends for the nine months ended December 31, 2022, consistent with the same period in 2021[26]. - The board did not recommend any dividend distribution for the nine months ended December 31, 2022, consistent with the same period in 2021[47]. Government Support - The company received government subsidies amounting to HKD 4.7 million during the nine months ended December 31, 2022[22]. - Other income increased to approximately HKD 5.1 million for the nine months ended December 31, 2022, compared to HKD 0.4 million in the same period of 2021, primarily due to government subsidies received under the anti-epidemic fund[39]. Corporate Governance - The company has maintained compliance with corporate governance codes and continues to review its practices to ensure adherence[49]. - The audit committee has reviewed the unaudited consolidated results for the nine months ended December 31, 2022, and confirmed compliance with applicable accounting standards and regulations[52]. Shareholder Information - As of December 31, 2022, major shareholders, including Mr. Ye and Ms. Fu, hold 514.5 million shares, representing 64.31% of the company[55]. - No stock options have been granted, exercised, or canceled under the stock option plan since its adoption, and there are no unexercised stock options as of December 31, 2022[62]. - The stock option plan aims to attract, retain, and reward qualified individuals contributing to the group, enhancing the interests of the company and its shareholders[62]. - There are no arrangements made for directors to acquire shares or debt securities of the company or any other corporation, nor have any rights been granted to directors or their immediate family members[64]. - No directors or their associates are engaged in any business that directly or indirectly competes with the group as of December 31, 2022[65]. Business Expansion - The company opened a flagship center in Mong Kok in May 2021 and a new center in Tsim Sha Tsui in June 2022 to expand its operations[32]. - The company plans to leverage its strong customer base and reputation to drive steady business growth and maximize shareholder value in the future[35]. Impact of COVID-19 - The group recorded a net profit of approximately HKD 2.1 million for the nine months ended December 31, 2022, down from HKD 12.6 million in the same period of 2021, primarily due to the impact of COVID-19 and the temporary closure of medical beauty centers[46].

Financial Performance - For the six months ended September 30, 2022, the group's revenue was approximately HKD 96.5 million, a decrease of 13.5% compared to HKD 111.2 million for the same period in 2021[21] - The net profit for the same period was approximately HKD 2.0 million, down 79.6% from HKD 9.8 million in the previous year[21] - Basic earnings per share for the period were HKD 0.09, a decrease from HKD 0.25 in the previous year[24] - Total comprehensive income for the period was HKD 2.0 million, compared to HKD 9.8 million in the previous year[24] - The company recorded a total comprehensive income of HKD 2,007,000 for the six months ended September 30, 2022, improving from a total comprehensive loss of HKD 9,770,000 in the same period of 2021[35] - Net profit for the six months ended September 30, 2022, was approximately HKD 2.0 million, down from HKD 9.8 million in the same period of 2021[95] Dividends - The board of directors did not recommend the distribution of dividends for the six months ended September 30, 2022, compared to zero dividends for the same period in 2021[21] - The company did not declare any dividends for the six months ended September 30, 2022, consistent with the previous year[58] - The company does not recommend the distribution of an interim dividend for the six months ended September 30, 2022[103] Assets and Liabilities - The group's non-current assets as of September 30, 2022, amounted to HKD 173.9 million, a slight decrease from HKD 179.1 million as of March 31, 2022[27] - Current assets totaled HKD 52.8 million as of September 30, 2022, an increase from HKD 40.5 million as of March 31, 2022[27] - The group's total liabilities were HKD 120.5 million as of September 30, 2022, compared to HKD 116.1 million as of March 31, 2022[32] - The company’s total liabilities as of September 30, 2022, included current liabilities of HKD 120,513,000, primarily due to contract liabilities of HKD 115,590,000[42] - The total outstanding debt as of September 30, 2022, was approximately HKD 83.9 million, down from HKD 94.4 million as of March 31, 2022[98] - As of September 30, 2022, the company's debt-to-equity ratio was 1,631.5%, a decrease from 3,051.2% on March 31, 2022[112] Cash Flow - For the six months ended September 30, 2022, the company reported a net cash inflow from operating activities of HKD 23,339,000, compared to HKD 14,679,000 for the same period in 2021, representing a year-over-year increase of 58.1%[38] - Cash and cash equivalents increased by HKD 17,649,000 during the six months ended September 30, 2022, compared to a decrease of HKD 9,450,000 in the same period of 2021[38] - The company’s cash and cash equivalents at the beginning of the period were HKD 1,642,000, compared to HKD 39,377,000 at the beginning of the same period in 2021[38] - Cash and bank balances were approximately HKD 193 million as of September 30, 2022, compared to HKD 1.6 million as of March 31, 2022[98] Income and Expenses - The group reported a significant increase in other income to HKD 4.6 million from HKD 0.26 million in the previous year[24] - The company received government subsidies amounting to HKD 4,272,000 during the six months ended September 30, 2022, while no subsidies were recorded in the same period of 2021[52] - Employee costs totaled HKD 39,825,000 for the six months ended September 30, 2022, an increase of 11.5% from HKD 35,902,000 in the same period of 2021[53] - Employee costs rose to approximately HKD 39.8 million from HKD 35.9 million, attributed to an increase in the number of employees[88] - Depreciation expenses for property, plant, and equipment increased to approximately HKD 12.8 million from HKD 8.3 million, due to the acquisition of new assets[90] Strategic Initiatives - The company plans to implement several strategies to increase revenue, including active negotiations with banks for credit financing and financial support from major shareholders[42] - The company’s management believes that the strategic expansion of its medical beauty center network will enhance its competitive advantage and profitability[78] - The company opened new flagship centers in Mong Kok and a new center in Tsim Sha Tsui to expand its operations[78] Shareholder Information - The major shareholders, Equal Joy, hold 562,000,000 shares, representing 70.25% of the company's equity[131] - The board of directors and major shareholders have no interests in any competing businesses as of September 30, 2022[145] - The executive directors include Mr. Ye Zhen Guo and Ms. Fu Zhi Qing, with independent non-executive directors also listed[147] Compliance and Governance - The company has maintained compliance with all applicable corporate governance codes and standards as of September 30, 2022[123] - There were no significant investments, acquisitions, or disposals of subsidiaries or capital assets during the reporting period[111] - The company reported no significant contingent liabilities as of September 30, 2022, remaining unchanged from zero on March 31, 2022[116] - The company has not experienced any significant impact on its operating cash flow due to exchange rate fluctuations, as most transactions are denominated in HKD[115] Other Information - There were no major events occurring after September 30, 2022, that would impact the company's financial position[120] - The company has not purchased, sold, or redeemed any of its listed securities during the six months ending September 30, 2022[128] - The company has no plans for significant investments or capital assets as of September 30, 2022[111] - The company has adopted a share option scheme to reward and incentivize qualified individuals for their contributions, effective for ten years from September 21, 2018[141] - As of September 30, 2022, there have been no share options granted, exercised, or cancelled under the share option scheme[141] - There are no outstanding share options, warrants, derivatives, or convertible securities as of the report date[141]

Financial Performance - For the three months ended June 30, 2022, the group's revenue was approximately HKD 44.0 million, a decrease of 16.5% from HKD 52.5 million in the same period of 2021[21]. - The group generated a net profit of approximately HKD 1.0 million for the three months ended June 30, 2022, down 80.4% from a net profit of HKD 5.1 million in the same period of 2021[21]. - Total comprehensive income for the period was HKD 1.0 million, significantly lower than HKD 5.1 million in the same period of 2021[24]. - Basic earnings per share for the three months ended June 30, 2022, was HKD 0.13, a decrease of 79.2% from HKD 0.64 in the same period of 2021[24]. - Profit for the same period was approximately HKD 1.0 million, down from HKD 5.1 million in the previous year, primarily due to the impact of COVID-19 and the temporary closure of medical beauty centers[74]. Revenue Breakdown - Revenue from treatment services for the three months ended June 30, 2022, was HKD 42,765,000, a decrease of 16.3% compared to HKD 51,389,000 for the same period in 2021[36]. - Total revenue for the three months ended June 30, 2022, was HKD 43,956,000, down from HKD 52,459,000 in the same period of 2021, representing a decline of 16.2%[36]. - The company's revenue for the three months ended June 30, 2022, was approximately HKD 44.0 million, a decrease of about HKD 8.5 million or 16.2% compared to the same period in 2021[57]. Dividends - The board of directors did not recommend the distribution of dividends for the three months ended June 30, 2022, consistent with no dividends declared in 2021[21]. - The company did not recommend any dividend for the three months ended June 30, 2022, consistent with the previous year[48]. - The company does not recommend the distribution of dividends for the three months ended June 30, 2022[75]. Expenses and Costs - The total employee costs for the three months ended June 30, 2022, were HKD 16,294,000, slightly down from HKD 16,651,000 in the same period of 2021, a decrease of 2.2%[38]. - The total marketing and promotional expenses for the three months ended June 30, 2022, were HKD 3,984,000, down from HKD 4,677,000 in the same period of 2021, a decrease of 14.8%[38]. - The cost of inventory and consumables for the three months was approximately HKD 7.1 million, down from HKD 7.8 million, consistent with the decline in revenue[62]. - Employee costs decreased to approximately HKD 16.3 million from HKD 16.7 million, attributed to the business being forced to close for a period due to COVID-19[66]. Other Income - The group reported other income of HKD 2.33 million for the three months ended June 30, 2022, compared to HKD 0.15 million in the same period of 2021[24]. - Other income for the three months ended June 30, 2022, was HKD 2,330,000, significantly up from HKD 147,000 in the same period of 2021[43]. - Other income increased to approximately HKD 2.3 million from HKD 0.1 million, mainly due to government subsidies received under the anti-epidemic fund[63]. Asset Management - The group's total assets as of June 30, 2022, were approximately HKD 64.1 million, reflecting a stable asset base[30]. Strategic Focus - The company continues to focus on expanding its skincare product offerings and enhancing service delivery in Hong Kong[30]. - The group is committed to ongoing research and development to innovate new products and improve existing services[30]. - The company aims to enhance its market penetration and profitability through strategic expansion of its medical beauty center network[56]. - The outlook for the medical beauty services industry remains optimistic despite uncertainties caused by COVID-19, with the company planning to leverage its strong customer base and reputation for steady business growth[60]. Operational Challenges - The company closely monitors the impact of COVID-19 on its financial condition and operational performance, indicating ongoing challenges in the market[53]. Shareholder Information - The major shareholders, Mr. Ye and Ms. Fu, each hold a 75% equity interest in the company through Equal Joy, which owns 600,000,000 shares[87][88]. - The company has a total of 600,000,000 shares held by Equal Joy, representing a significant portion of the equity structure[93]. - The board of directors consists of Mr. Ye and Ms. Fu as executive directors, along with independent non-executive directors[103]. Share Option Scheme - The company has not granted, exercised, or cancelled any options under the share option scheme since its adoption, and there are no outstanding options, warrants, or convertible securities as of June 30, 2022[97]. - The share option scheme aims to attract, retain, and reward eligible individuals for their contributions to the group, and it is valid for ten years unless terminated by shareholders[97]. - The company has not disclosed any other interests or holdings in shares or related securities by directors or major executives as of June 30, 2022[91][96]. - There were no known interests or holdings in competing businesses by directors or their associates during the three months ended June 30, 2022[101]. - The company has not established any arrangements for directors to benefit from acquiring shares or debt securities of the company or any other corporation[100].

Financial Performance - The group's revenue for the year ended March 31, 2022, was approximately HKD 179.6 million, an increase of about HKD 97.5 million or 118.8% compared to approximately HKD 82.1 million for the year ended March 31, 2021[14]. - The net loss for the year ended March 31, 2022, was approximately HKD 8.8 million, compared to a net loss of approximately HKD 27.0 million in the previous year[14]. - The significant revenue increase was primarily due to the opening of a new flagship center in Mong Kok in May 2021 and improved consumer sentiment as the COVID-19 pandemic situation was brought under control[25]. - The company reported a net loss of approximately HKD 8.8 million for the year, a decrease from a net loss of HKD 27.0 million in the previous year, attributed to the substantial increase in revenue[37]. - The company aims to maximize shareholder value by leveraging its solid customer base and good reputation to drive steady business growth[24]. Dividend Policy - The company did not recommend the distribution of a final dividend for the year ended March 31, 2022, consistent with no dividend in the previous year[14]. - The board does not recommend the payment of a final dividend for the year ended March 31, 2022[87]. - The company did not recommend any dividend payment for the year ended March 31, 2022, consistent with the previous year[38]. Operational Impact of COVID-19 - The COVID-19 pandemic significantly impacted the business environment in Hong Kong, leading to the closure of medical beauty centers from January to April 2022 due to government measures[17]. - The economic difficulties caused by the pandemic weakened customer willingness to undergo medical beauty treatments, negatively affecting the company's revenue over the past few years[17]. - The company is closely monitoring the impact of the COVID-19 pandemic on its financial condition and operational performance[155]. Business Operations - The company operates medical beauty centers under the "per Face" brand, providing non-surgical medical beauty services[17]. - The company aims to provide comprehensive treatment solutions to help customers maintain and improve their skin conditions and appearance[17]. - The company opened new centers in Mong Kok and Tsim Sha Tsui to expand its operational scale and enhance market penetration[22]. Financial Position - As of March 31, 2022, the total equity of the group was approximately HKD 3.1 million, a decrease from HKD 11.9 million in 2021[41]. - The group's bank balances and cash as of March 31, 2022, were approximately HKD 1.6 million, down from HKD 39.4 million in 2021[41]. - The total outstanding debt of the group as of March 31, 2022, was HKD 94.5 million, compared to HKD 111.9 million in 2021[41]. - The group had a debt-to-equity ratio of 3,015.17% as of March 31, 2022, up from 940.1% in 2021, primarily due to a decrease in net asset value[46]. Governance and Compliance - The board of directors confirmed that the information provided in the announcement is accurate and complete, with no misleading or fraudulent elements[2]. - The company has adopted the corporate governance code as per GEM listing rules and has complied with all applicable provisions during the year[163]. - The audit committee has reviewed the audited consolidated financial statements for the year ending March 31, 2022, ensuring compliance with applicable accounting standards[156]. - The company ensures that all directors receive timely and comprehensive information to fulfill their responsibilities effectively[181]. Risks and Uncertainties - The company identified significant risks including potential regulatory changes in the medical beauty services sector that could increase operational costs and reduce profit margins[79]. - The company has experienced various risks and uncertainties that could impact its financial condition and operational performance[78]. - The company’s operations and demand for medical beauty services are significantly influenced by the economic, social, and political conditions in Hong Kong[82]. Share Option Scheme - The share option scheme aims to attract, retain, and reward eligible individuals contributing to the group[117]. - The total number of securities that can be issued under the share option plan is 80,000,000 shares, accounting for 10% of the total issued shares as of the annual report date[119]. - The maximum number of shares that can be issued due to the exercise of share options in any 12-month period is limited to 1% of the issued shares, unless approved by shareholders[121]. - Each eligible person must pay a nominal amount of HKD 1.00 when accepting the offer[124]. Employee Relations - The company has maintained good relationships with employees, customers, and suppliers, with no significant disputes reported as of March 31, 2022[85]. - Employee costs increased to approximately HKD 69.3 million from HKD 41.0 million, mainly due to reduced temporary closures of medical beauty centers and the opening of the new flagship center[29]. Charitable Contributions - Charitable donations made by the group amounted to approximately HKD 19,000 for the year, down from HKD 29,000 in 2021[97].

Financial Performance - The group's revenue for the year ended March 31, 2022, was approximately HKD 179.6 million, an increase of about HKD 97.5 million or 118.8% compared to approximately HKD 82.1 million for the year ended March 31, 2021[14]. - The net loss for the year ended March 31, 2022, was approximately HKD 8.8 million, compared to a net loss of approximately HKD 27.0 million in the previous year[14]. - Other income for the year ended March 31, 2022, was approximately HKD 5.6 million, a decrease from HKD 12.1 million in the previous year due to reduced government subsidies[28]. - Employee costs for the year ended March 31, 2022, were approximately HKD 69.3 million, up from HKD 41.0 million in the previous year, primarily due to increased operational days as centers reopened[29]. - The group incurred other expenses of approximately HKD 45.3 million for the year ended March 31, 2022, compared to HKD 30.8 million in the previous year, driven by increased marketing and promotional activities[36]. - Capital expenditure for the year ended March 31, 2022, was approximately HKD 45.7 million, significantly higher than HKD 16.1 million in the previous year, reflecting investments in equipment and renovations[42]. - The group’s total equity as of March 31, 2022, was approximately HKD 3.1 million, down from HKD 11.9 million in the previous year[41]. - The group’s bank balance and cash as of March 31, 2022, was approximately HKD 1.6 million, a decrease from HKD 39.4 million in the previous year[41]. - The company reported a reserve available for distribution to shareholders of approximately zero HKD as of March 31, 2022, compared to 20.2 million HKD in the previous year[93]. Business Operations - The significant revenue increase was primarily due to the opening of a new flagship center in Mong Kok in May 2021 and improved consumer sentiment as the COVID-19 situation was better controlled[18]. - The group opened a new flagship center in Mong Kok in May 2021 and a new center in Tsim Sha Tsui in June 2022 to expand its operational scale and enhance market penetration[22]. - New treatment equipment and consumables will be acquired to expand the range of services offered[18]. - The company plans to continue monitoring market conditions and strengthen its sustainable development strategies to capitalize on current opportunities despite ongoing uncertainties from the COVID-19 pandemic[24]. - The company remains optimistic about the industry outlook and plans to continue strategic business expansion and effective marketing efforts to achieve sustained growth[18]. Shareholder and Dividend Information - The company did not recommend the distribution of a final dividend for the year ended March 31, 2022, consistent with the previous year[14]. - The board did not recommend the payment of a final dividend for the year ended March 31, 2022[87]. Risk Management - The company identified various risks that could impact its financial condition and operational performance, including government policy risks and economic conditions in Hong Kong[78][82]. - The company is closely monitoring the impact of the COVID-19 pandemic on its financial condition and operational performance[56]. - The impact of the COVID-19 pandemic on the business environment remains uncertain, but the local economy is beginning to recover[18]. Corporate Governance - The company has adopted the corporate governance code as per GEM listing rules and has complied with all applicable provisions during the year[163]. - The board of directors consists of five members, including two executive directors and three independent non-executive directors, ensuring compliance with GEM listing rules[167]. - The company emphasizes the importance of board diversity, considering factors such as gender, age, cultural background, and professional qualifications[199]. - The company provides tailored training for newly appointed directors to ensure they understand their responsibilities and the company's operations[183]. - The company encourages continuous professional development for directors to keep their knowledge and skills updated[183]. Audit and Compliance - The audit committee has reviewed the audited consolidated financial statements for the year ended March 31, 2022, ensuring compliance with applicable accounting standards and GEM listing rules[156]. - The company appointed a new auditor, Changqing (Hong Kong) CPA Limited, on April 26, 2022, following the resignation of Kaiyuan Xinde CPA Limited[160]. - The Audit Committee held five meetings during the year to review the group's interim, quarterly, and annual performance, with all members in attendance[190]. Employee and Management Information - As of March 31, 2022, the company had a total of 159 employees, an increase from 117 employees in the previous year[43]. - The remuneration of directors and senior management is reviewed annually by the remuneration committee, considering the group's operating performance and market data[154]. - The Remuneration Committee conducted two meetings to approve the remuneration and performance bonuses for directors and senior management[193]. Shareholder Structure - The company has a total of 600,000,000 shares held by major shareholders, representing 75% ownership[106]. - The stock option plan allows for the issuance of up to 80,000,000 shares, which is 10% of the total issued shares as of the report date[119]. - The stock option plan aims to attract and retain qualified individuals to enhance the company's and shareholders' interests[117].

Financial Performance - For the nine months ended December 31, 2021, the group's revenue was approximately HKD 175.5 million, compared to HKD 58.8 million for the same period in 2020, representing an increase of 198.2%[16] - The group generated a net profit of approximately HKD 12.6 million for the nine months ended December 31, 2021, compared to a net loss of HKD 21.7 million for the same period in 2020, marking a significant turnaround[16] - The total comprehensive income for the period was HKD 12.6 million, a significant recovery from a total comprehensive loss of HKD 21.7 million in the previous year[18] - The group reported a pre-tax profit of HKD 12.2 million for the nine months ended December 31, 2021, compared to a pre-tax loss of HKD 22.0 million in the same period of 2020[18] - Revenue for the nine months ended December 31, 2021, reached HKD 175,478,000, a significant increase of 197.5% compared to HKD 58,838,000 for the same period in 2020[32] - Revenue from treatment services amounted to HKD 170,409,000, up from HKD 56,527,000 in the previous year, reflecting a growth of 201.5%[32] - The company reported a profit of approximately HKD 12.6 million for the same period, compared to a loss of approximately HKD 21.7 million in the previous year[61] Cost and Expenses - The gross profit margin improved significantly due to increased revenue and better cost management, with a gross profit of HKD 146.2 million for the nine months ended December 31, 2021[18] - Employee costs increased to HKD 56.8 million for the nine months ended December 31, 2021, compared to HKD 31.1 million in the same period of 2020, reflecting the expansion of the workforce[18] - The group incurred financing costs of HKD 3.7 million for the nine months ended December 31, 2021, compared to HKD 1.7 million in the same period of 2020, indicating increased borrowing[18] - Total employee costs for the nine months ended December 31, 2021, were HKD 56,834,000, significantly higher than HKD 31,061,000 in the previous year[36] - Inventory and consumables costs for the nine months ended December 31, 2021, were approximately HKD 29.2 million, up from HKD 9.2 million in the previous year, consistent with revenue growth[52] - The company incurred depreciation expenses of approximately HKD 13.1 million for property, plant, and equipment, up from HKD 8.9 million, mainly due to new property and equipment acquisitions[57] - Marketing and promotional expenses increased to approximately HKD 20.6 million from HKD 12.7 million, aimed at enhancing brand awareness and maintaining market share[60] Dividend and Shareholder Information - The board of directors did not recommend any dividend distribution for the nine months ended December 31, 2021, consistent with the previous year[16] - The company did not declare any dividends for the nine months ended December 31, 2021, consistent with the previous year[40] - Major shareholders, Mr. Ye and Ms. Fu, each hold 600,000,000 shares, representing 75% of the company's equity[70] - The company has not granted, exercised, or cancelled any share options under the share option scheme since its adoption[78] - There are no arrangements for directors to acquire shares or debt securities of the company during the nine months ended December 31, 2021[79] Operational Developments - The company continues to focus on expanding its skincare product offerings and enhancing service delivery in Hong Kong[25] - The company opened a new flagship center in Mong Kok in May 2021 and plans to open another center in Tsim Sha Tsui in the first half of 2022 to expand its operational scale[48] - The company remains optimistic about the medical beauty service industry despite uncertainties caused by the COVID-19 pandemic and plans to monitor market conditions closely[50] Compliance and Governance - The audit committee has been established in accordance with GEM Listing Rules and consists of three independent non-executive directors[66] - For the nine months ended December 31, 2021, the group’s unaudited consolidated performance was reviewed and deemed compliant with applicable accounting standards and GEM Listing Rules[66] - No purchase, sale, or redemption of the company's listed securities occurred during the nine months ended December 31, 2021[68] - No directors or their associates engaged in any business that competes directly or indirectly with the group during the reporting period[81] Impact of COVID-19 - The company continues to monitor the impact of COVID-19 on its financial performance and operations, with potential negative effects anticipated[45]

Financial Performance - For the six months ended September 30, 2021, the group's revenue was approximately HKD 111.2 million, a significant increase from HKD 35.3 million for the same period in 2020, representing a growth of 215%[17]. - The group reported a net profit of approximately HKD 9.8 million for the six months ended September 30, 2021, compared to a net loss of HKD 14.4 million for the same period in 2020, marking a turnaround in performance[17]. - The company reported a net profit of HKD 9,770,000 for the six months ended September 30, 2021, compared to a net loss of HKD 14,385,000 for the same period in 2020, indicating a significant turnaround[25]. - Revenue from treatment services reached HKD 108,497,000 for the six months ended September 30, 2021, a substantial increase from HKD 33,811,000 in the previous year, reflecting a growth of approximately 220%[36]. - The net cash generated from operating activities was HKD 14,679,000, compared to HKD 4,609,000 in the prior year, showing an increase of about 218%[27]. - The company recorded a total comprehensive income of HKD 21,680,000 as of September 30, 2021, up from HKD 24,484,000 in the previous year[25]. - The company’s total revenue for the six months ended September 30, 2021, was HKD 111,192,000, compared to HKD 35,262,000 in the previous year, marking an increase of approximately 215%[36]. - The increase in revenue was primarily due to the absence of COVID-19 related closures that affected the medical beauty centers in the same period of 2020 and the revenue generated from new centers opened in May 2021[68]. Dividends and Shareholder Returns - The board of directors did not recommend the distribution of dividends for the six months ended September 30, 2021, consistent with the previous year where no dividends were declared[17]. - The company did not declare any dividends for the six months ended September 30, 2021, consistent with the same period in 2020[47]. - The company did not recommend any interim dividend for the six months ended September 30, 2021, consistent with the previous year[85]. Assets and Liabilities - Total assets less current liabilities amounted to HKD 88.988 million as of September 30, 2021, slightly down from HKD 90.367 million as of March 31, 2021[21]. - Non-current assets increased to HKD 175.003 million as of September 30, 2021, compared to HKD 176.821 million as of March 31, 2021[21]. - The group’s total liabilities were HKD 156.815 million as of September 30, 2021, compared to HKD 156.570 million as of March 31, 2021, indicating stable liability management[23]. - The company has a net current liability of HKD 86,015,000, primarily due to contract liabilities of HKD 107,382,000, which are expected to generate cash inflows without leading to cash outflows[30]. - As of September 30, 2021, the company's total equity was approximately HKD 21.7 million, up from approximately HKD 11.9 million as of March 31, 2021[81]. - The company reported unsecured and secured bank borrowings of approximately HKD 15.0 million as of September 30, 2021, down from approximately HKD 17.6 million on March 31, 2021[99]. - The company had cash and bank balances of approximately HKD 29.9 million as of September 30, 2021, down from approximately HKD 39.4 million as of March 31, 2021[81]. - The company’s debt-to-equity ratio was 464.0%, a significant decrease from 940.1% on March 31, 2021[94]. Employee Costs and Investments - The group’s employee costs rose to HKD 35.902 million for the six months ended September 30, 2021, compared to HKD 18.433 million for the same period in 2020, indicating increased workforce investment[19]. - Total employee costs increased to HKD 35,902,000 for the six months ended September 30, 2021, from HKD 18,433,000 in the previous year, representing an increase of approximately 95%[40]. - The average salary for key management personnel increased to HKD 3,071,000 for the six months ended September 30, 2021, from HKD 2,093,000 for the same period in 2020[61]. - Capital expenditure for the six months ended September 30, 2021, was approximately HKD 15.9 million, which included the purchase of treatment equipment and renovations, compared to HKD 3.4 million in the same period in 2020[84]. - The group purchased property, plant, and equipment totaling approximately HKD 15,884,000 for the six months ended September 30, 2021, compared to HKD 3,356,000 for the same period in 2020[51]. Market and Operational Strategy - The company plans to open a new center in Tsim Sha Tsui by the end of 2021 to expand its operational scale and enhance profitability[64]. - The company aims to increase its service offerings to enhance its competitive advantage as it expands its network of medical beauty centers[64]. - The company plans to closely monitor market conditions and strengthen its sustainable development strategies to overcome current adversities while maximizing shareholder value[67]. - The company continues to monitor regulatory changes in the medical beauty service sector, which may impact operational costs and profit margins[90]. Governance and Compliance - The company has maintained compliance with corporate governance codes and has established an audit committee to oversee financial reporting[105]. - The company has not purchased, sold, or redeemed any of its listed securities during the reporting period[107]. - No directors or their associates engaged in any business that directly or indirectly competes with the group during the reporting period[119]. Miscellaneous - The company did not receive any government subsidies during the current period, contrasting with HKD 6,512,000 received in the same period last year[38]. - Other income decreased to approximately HKD 0.3 million from HKD 7.5 million in the previous year, mainly due to the absence of government subsidies under the anti-epidemic fund during the period[71]. - The deferred tax expense for the period was HKD 186,000, compared to HKD 40,000 in the previous year, indicating an increase in tax obligations[41]. - There were no significant contingent liabilities as of September 30, 2021, compared to zero on March 31, 2021[97]. - The company has not experienced any significant impact from foreign exchange fluctuations, as most transactions are conducted in HKD[96]. - The company has no major plans for significant investments or capital assets as of September 30, 2021[92]. - The stock option plan was adopted to attract, retain, and reward eligible individuals for their contributions to the group, effective for ten years unless terminated by a resolution at a shareholders' meeting[115][116]. - No stock options, warrants, or convertible securities have been granted, exercised, or cancelled since the adoption of the stock option plan[116].

Financial Performance - For the three months ended June 30, 2021, the group's revenue was approximately HKD 52.5 million, compared to HKD 18.8 million for the same period in 2020, representing an increase of 179%[17]. - The group generated a net profit of approximately HKD 5.1 million for the three months ended June 30, 2021, compared to a net loss of HKD 4.8 million for the same period in 2020[17]. - The total comprehensive income for the period was HKD 5.1 million, compared to a total comprehensive loss of HKD 4.8 million in the previous year[19]. - Basic earnings per share for the three months ended June 30, 2021, were HKD 0.64, compared to a loss per share of HKD 0.60 for the same period in 2020[19]. - The group reported a profit before tax of HKD 5,127,000 for the three months ended June 30, 2021, compared to a loss of HKD 4,789,000 in the same period of 2020[40]. Revenue Breakdown - Revenue from treatment services reached HKD 51,389,000 for the three months ended June 30, 2021, compared to HKD 18,030,000 in the same period of 2020, representing an increase of 185.5%[32]. - Total revenue for the group was HKD 52,459,000 for the three months ended June 30, 2021, compared to HKD 18,817,000 in the same period of 2020, marking a growth of 178.5%[32]. - For the three months ended June 30, 2021, the company's revenue was approximately HKD 52.5 million, an increase of about HKD 33.7 million or 179.3% compared to the same period in 2020[47]. Cost and Expenses - Employee costs for the three months ended June 30, 2021, were HKD 16.7 million, up from HKD 8.3 million in the same period in 2020, reflecting a 100% increase[19]. - The total employee costs amounted to HKD 16,651,000 for the three months ended June 30, 2021, up from HKD 8,339,000 in the same period of 2020, reflecting a 99.5% increase[35]. - The cost of inventory and consumables for the three months ended June 30, 2021, was approximately HKD 7.8 million, up from HKD 2.8 million in the same period of 2020, consistent with revenue growth[51]. - Depreciation expenses for property, plant, and equipment rose to approximately HKD 3.9 million from HKD 2.9 million, attributed to new property and equipment acquisitions[56]. - The financing costs for the three months ended June 30, 2021, were HKD 1.3 million, compared to HKD 0.5 million in the same period in 2020, indicating a 174% increase[19]. - Deferred tax expenses were HKD 468,000 for the three months ended June 30, 2021, compared to HKD 247,000 in the same period of 2020, an increase of 89.5%[37]. Dividend Policy - The board of directors did not recommend the distribution of dividends for the three months ended June 30, 2021, consistent with no dividends declared in 2020[17]. - The group did not recommend any dividend for the three months ended June 30, 2021, consistent with the previous year[39]. - The company did not recommend any dividend distribution for the three months ended June 30, 2021, consistent with the previous year[61]. Strategic Plans - The group plans to expand its market presence and enhance product offerings in the upcoming quarters[25]. - The company is focused on developing new technologies and products to drive future growth and profitability[25]. - The company plans to expand its operations by opening new centers to capture growing customer demand and enhance market penetration in Hong Kong[46]. - The company aims to maximize shareholder value by leveraging its strong customer base and reputation to drive steady business growth[49]. - The company has expanded its service offerings to include training courses recognized under the Hong Kong Qualifications Framework for laser and light beauty treatments[46]. Shareholder Information - As of June 30, 2021, Mr. Ye and Ms. Fu each hold 600,000,000 shares in Equal Joy, representing a 75% equity stake[69]. - Equal Joy is jointly owned by Mr. Ye and Ms. Fu, each holding a 50% beneficial interest in the total issued shares[70]. - The weighted average number of ordinary shares issued was 800,000 for both the three months ended June 30, 2021, and 2020, indicating no change in share structure[42]. - No other directors or key executives have disclosed any interests or short positions in the company's shares or related securities as of June 30, 2021[72]. - The company has adopted a share option scheme to attract and reward qualified individuals, effective for ten years from September 21, 2018[77]. - No share options have been granted, exercised, or cancelled under the share option scheme since its adoption[77]. - As of June 30, 2021, the company has no unexercised share options, warrants, derivatives, or convertible securities[77]. - There are no arrangements for directors to acquire shares or debt securities of the company or any other corporation[79]. - No directors or their associates are engaged in any business that competes directly or indirectly with the group[80]. - The board of directors includes Mr. Ye and Ms. Fu as executive directors, with independent non-executive directors also serving[81]. Other Income - The group reported other income of HKD 147,000 for the three months ended June 30, 2021, significantly down from HKD 4,039,000 in the same period of 2020[35]. - Other income decreased to approximately HKD 0.1 million from HKD 4.0 million, primarily due to the absence of government subsidies during the period[53]. COVID-19 Impact - The group continues to monitor the impact of COVID-19 on its financial performance and operations, indicating ongoing strategic adjustments[44]. - The group applied new Hong Kong Financial Reporting Standards effective from April 1, 2021, with no significant impact on the financial statements for the current and prior periods[30].